Impact of cancer diagnosis on persistence of oral antidiabetic drugs

Cardiometabolic Comorbidities in Cancer Survivors

“… 4 For example, a cancer diagnosis has been associated with significant declines in adherence to evidence-based treatments for diabetes, hypertension, and lipid disorders. 4 , 38 , 148 , 149 Specifically, in a retrospective study, adherence to orally administered hypoglycemic agents, renin-angiotensin-aldosterone system inhibitors, and statins decreased 3.7%, 5.3%, and 3.2%, respectively, following an incident cancer diagnosis. 38 …”

“…Changes in medication adherence following a cancer diagnosis vary by cancer type, patient demographic, and clinical characteristics. Research has demonstrated that significant decreases in adherence to orally administered antidiabetic medications and statins occurred in patients with a lung or colorectal cancer diagnosis 148 , 149 , 150 ; however, declines in medication adherence for pre-existing diabetes, dyslipidemia, and hypertension were similar between breast and prostate cancer patients and matched noncancer cohorts. 150 In addition, larger declines in medication adherence were observed in older adults, multiracial patients, and those diagnosed with advanced cancer.…”

“… 150 In addition, larger declines in medication adherence were observed in older adults, multiracial patients, and those diagnosed with advanced cancer. 4 , 148 , 149 One study found that patients with stage IV cancer experienced a 10.7% decline in adherence to glucose-lowering mediations (compared with a 3.2% and 5.8% decrease in patients with stage II and III cancer, respectively) 4 , 148 , 149 ; another study only observed significant decreases in statin adherence among non-Hispanic Whites and multiracial patients. 4 , 148 , 149 …”